We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

33 hedge funds and large institutions have $37.9M invested in Viking Therapeutics in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

885% more capital invested

Capital invested by funds: $3.85M → $37.9M (+$34.1M)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

83% more funds holding

Funds holding: 18 → 33 (+15)

19.34% more ownership

Funds ownership: 7.3% → 26.64% (+19%)

Holders
33
Holders Change
+15
Holders Change %
+83.33%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
8
Reduced
1
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$5.39M
2
SCM
Sio Capital Management
New York
+$3.63M
3
Millennium Management
Millennium Management
New York
+$2.04M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.88M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.45M

Top Sellers

Rank Fund Capital Flow
1
AC
Ascend Capital
California
-$932K
2
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$180K
3
Citadel Advisors
Citadel Advisors
Florida
-$108K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$98K
5
VF
Virtu Financial
New York
-$70K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
1
Sphera Funds Management
Israel
$8.71M +$5.39M +1,855,300 +640%
SCM
2
Sio Capital Management
New York
$5.08M +$3.63M +1,250,250 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$4M +$1.88M +646,963 +191%
Renaissance Technologies
4
Renaissance Technologies
New York
$3.67M +$1.45M +500,700 +124%
Millennium Management
5
Millennium Management
New York
$2.85M +$2.04M +702,972 New
PWAM
6
Park West Asset Management
California
$2.44M +$1.16M +400,000 +200%
OM
7
Opaleye Management
Massachusetts
$1.95M +$1.4M +480,558 New
PVI
8
Pura Vida Investments
New York
$1.76M +$1.26M +433,900 New
EI
9
EAM Investors
California
$1.54M +$1.1M +378,520 New
EGI
10
EAM Global Investors
California
$1M +$716K +246,520 New
DMK
11
David M. Knott
$942K +$674K +232,000 New
IHM
12
Iguana Healthcare Management
New York
$913K +$653K +225,000 New
Victory Capital Management
13
Victory Capital Management
Texas
$791K +$566K +194,930 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$477K +$251K +86,355 +276%
CC
15
Cornerstone Capital
California
$352K +$252K +86,650 New
Creative Planning
16
Creative Planning
Kansas
$284K +$174K +60,000 +600%
IBT
17
International Biotechnology Trust
United Kingdom
$284K +$203K +70,000 New
BFM
18
Boothbay Fund Management
New York
$216K +$154K +53,158 New
Northern Trust
19
Northern Trust
Illinois
$163K +$67.1K +23,090 +136%
AGM
20
Alpine Global Management
New York
$162K +$116K +40,000 New
IWM
21
IHT Wealth Management
Illinois
$60K +$34.1K +11,725 New
FPF
22
FNY Partners Fund
New York
$60K +$43.6K +15,000 New
SKK
23
Shepherd Kaplan Krochuk
Massachusetts
$55K -$180K -62,000 -82%
IGGA
24
Iron Gate Global Advisors
Utah
$44K +$31.3K +10,778 New
UBS Group
25
UBS Group
Switzerland
$41K +$29K +10,000 New
1
2

VKTX Hedge Fund Activity: Q4 2017 in Review

33 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2017, worth a combined $37.9M — up 885% from $3.85M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new VKTX positions and 7 closed out — a net gain of 15 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $5.39M. The largest seller was Ascend Capital, exiting entirely with an estimated $932K sold.

  • 33 institutional investors held Viking Therapeutics (VKTX) as of Q4 2017, up from 18 in Q3 2017.
  • Funds reported $37.9M of Viking Therapeutics stock for Q4 2017, up 885% quarter-over-quarter.
  • 22 funds opened new Viking Therapeutics positions in Q4 2017 and 7 closed out, a net change of +15 holders.
  • The largest Viking Therapeutics buyer in Q4 2017 was Sphera Funds Management, an estimated $5.39M added.
  • The largest Viking Therapeutics seller in Q4 2017 was Ascend Capital, an estimated $932K sold.

Based on aggregated 13F filings for Q4 2017.